Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population
about
Two faces of p53: aging and tumor suppressionCaloric restriction: is mammalian life extension linked to p53?Chronic disease in men with newly diagnosed cancer: a nested case-control studyThe emergence of human-evolutionary medical genomicsTP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carcinoma in northeast Brazil.Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans.The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma riskTrade-offs between cancer and other diseases: do they exist and influence longevity?TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort.Genome maintenance and human longevity.The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammationSIRT6 minor allele genotype is associated with >5-year decrease in lifespan in an aged cohort.Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model.TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.TP53 and XRCC1 polymorphisms and breast cancer prognosis: a case-case study.The Regulation of Aging and Longevity: A New and Complex Role of p53.TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study.TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells.Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over timePolygenic effects of common single-nucleotide polymorphisms on life span: when association meets causality.Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies.Genetic epidemiology in aging research.Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patientsp53 polymorphisms: cancer implications.Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.Using mice to examine p53 functions in cancer, aging, and longevity.Is cellular senescence an example of antagonistic pleiotropy?Telomeres and human health.Human genetic variation and the risk of hepatocellular carcinoma development.Dysfunction of the MDM2/p53 axis is linked to premature aging.Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.The emerging role of alternative splicing in senescence and aging.TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto's thyroiditis.Human TP53 polymorphism (rs1042522) modelled in mouse does not affect glucose metabolism and body composition.Peripheral blood leukocyte telomere length and mortality among 64,637 individuals from the general population.Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.Assessment of lipid peroxidation and p53 as a biomarker of carcinogenesis among workers exposed to formaldehyde in the cosmetic industry.TP53 codon 72 polymorphism in pigmentary phenotypes.
P2860
Q24681014-5B80BED3-C1BD-4E4E-BBAB-E5703D004A65Q26829232-3D905F21-F05C-4D3C-98F7-0F271F4480CBQ28397580-918053C1-530D-4B5D-ADF6-B61C22E9CC5DQ28729955-9E3F7E8A-935C-4E2C-B536-C8C4D2DCF50BQ33671908-1F07743F-5134-4624-A652-62F4B5CF0E84Q33766324-B73746E9-C28A-474C-B390-4F6C87C68CB4Q33809241-178F0336-C542-4179-B15C-945C58418240Q34156039-BC2188DD-B6CC-4B60-8494-A71C65F48B5BQ34222645-B78D9889-592D-410B-964D-1AA07D45AD35Q34235876-101CF8B6-0769-4421-A189-C6F4EB7D0CEDQ34434759-F9572301-82D6-4A89-B214-BD240201E4CDQ34742708-4C860293-EBAF-4A6A-B847-35AF1FFE74AFQ34776699-49D27182-3029-48FC-9E7F-109E30ABE0E5Q35050803-29DE4658-F94E-4B53-BA68-CA1307D1970EQ35077721-E28DCF44-641C-406C-AB37-D7EE78158DB7Q35087169-45A06895-98DE-432D-8AE3-2B37214E6C6BQ35103174-F718868A-04AA-4742-AAC2-0F2BD3B9DADFQ35368917-76C9A9A5-787E-49BF-AE47-F13F8EC27DCBQ35611930-3A30FA45-21AC-462D-82C7-B7B36A5BA8EBQ35799814-C9DB1824-A5DB-4371-A5DE-AEADE1C687E8Q35969007-E9A4AFE6-9C5F-4446-97E8-899DC088167EQ36166448-34C2A7C7-B0BA-4E62-9ED9-5A852FCEEC2BQ37153090-C4486645-9806-48FA-A2AC-C732EAAA4FD9Q37214302-024E84BC-AAA9-4F38-8737-10E46B6C6669Q37351439-E14880AA-DD7D-4051-A81C-752E63B3281AQ37376012-6773B70B-A959-4737-8C43-3E9E01D5286EQ37699997-40549DF6-4B96-47A6-BE1B-EE026FDA1570Q37748214-27B6675A-6D85-4EBE-A758-06108B0CF12AQ37983630-8AE427DB-59E2-4360-B23D-C65492EBA4EBQ38152802-DCC14CD2-46C5-4E6F-9914-E602718A8BB9Q38552272-DA777321-E6A0-4B8E-814C-5B11D27BD187Q38605937-CF515221-1096-4F14-8D44-71ECFFA35495Q39403723-4848AC20-44AF-4762-9DEF-B017EC6BF7E7Q39432413-E239C6AE-ABD9-4D8E-8161-FE01D8E394FFQ40984767-10219D99-F458-48D6-89B9-FA7168081D9DQ41952567-FABAD817-A26D-43C2-87A4-AFD909FBE2F4Q44430361-5737269A-D0F8-4172-8F3D-23505611CFACQ46133689-056B34A7-E215-434B-B7EA-6C29ADE77221Q46319820-C5F71EE1-464A-47F1-821F-2295FA7B782EQ50251932-2ED6E1EE-5463-44C4-99AA-B40D8B833D32
P2860
Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@ast
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@en
type
label
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@ast
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@en
prefLabel
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@ast
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@en
P2860
P50
P356
P1476
Tumor suppressor p53 Arg72Pro ...... ncer in the general population
@en
P2093
Børge Grønne Nordestgaard
David Dynnes Ørsted
P2860
P304
P356
10.1084/JEM.20062476
P407
P577
2007-05-29T00:00:00Z